Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Blackstone Life Sciences
Deal Size : $337.0 million
Deal Type : Funding
Details : Funding will support Medtronic's Diabetes R&D, including a series of near-term programs such as the MiniMed™ 780G insulin pump system, its Personalized Closed Loop (PCL) system, extended wear infusion set, and Zeus and Synergy sensors.
Product Name : MiniMed 780G
Product Type : Hormone
Upfront Cash : Undisclosed
December 06, 2020
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Blackstone Life Sciences
Deal Size : $337.0 million
Deal Type : Funding
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The 770G System is a first-of-a-kind device for patients aged 2 to 6 years. It is the first legally marketed device that can automatically adjust insulin delivery based on continuous glucose monitor values for this patient population.
Product Name : MiniMed 770G
Product Type : Hormone
Upfront Cash : Inapplicable
January 09, 2020
Lead Product(s) : Insulin
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
